Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript

May 8, 2025 / 08:30 PM GMT

Release Date Price: €27.8 (+3.73%)

Transcript 10-Q8-K

Key Points

Positve

Crinetics Pharmaceuticals Inc (CRNX) is strategically positioned for long-term sustainable growth with a focus on the anticipated commercial launch of their first products this year.
The company has a robust pipeline, including two late-stage candidates and three additional candidates in pre-clinical studies.
Crinetics Pharmaceuticals Inc (CRNX) has a strong financial position with $1.3 billion on the balance sheet, allowing continued investment in their pipeline and support for prospective launches.
The anticipated launch of Paltustine for acromegaly is a pivotal milestone, with positive feedback from healthcare professionals and strong patient advocacy partnerships.
Regulatory engagement with the FDA and European Medicines Agency is proceeding on track, with no disruptions anticipated for the Paltustine NDA review.

Negative

Research and development expenses increased by 43% compared to the same period in 2024, primarily due to additional personnel and increased manufacturing costs.
Selling, general, and administrative expenses rose by 71% compared to the same period in 2024, driven by growth to support ongoing programs and the planned commercial launch.
Cash used in operations increased significantly, with expectations for cash use in operations to be between $340 and $380 million for 2025.
The company anticipates a measured uptake of Paltustine during early launch, with coverage expected to build progressively over the first 6 to 9 months.
There is a significant unmet need for safe, highly efficacious, easy-to-administer treatments, indicating challenges in meeting current market demands.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRNX.OQ - Crinetics Pharmaceuticals Inc
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call
May 08, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Welcome to the Cronetics Pharmaceuticals 1st quarter 2025 financial results conference call.

At this time, all participants are in this and only mode. Following the management's prepared remarks, we will hold a question and answer session.

Please press followed by 1 on your telephone keypad. If you change your mind, please press star followed by 2.

And I like to turn the call over toay Ari Tuwaka, head of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, operator. Good afternoon, everyone,

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.